Association of Polyphenol Biomarkers with Cardiovascular Disease and Mortality Risk: A Systematic Review and Meta-Analysis of Observational Studies

Epidemiologic studies have suggested an inverse association between flavonoids and cardiovascular disease (CVD). However, the results might have been influenced by the use of dietary assessment methods, which are error prone. The aim of this paper was to systematically review and analyse the literature for evidence of associations between polyphenol biomarkers and CVD and mortality risk in observational studies. Eligible studies were identified through PubMed, Web of Science, and reference lists. Multivariable adjusted associations were extracted. Data were log-transformed and pooled using the random effects model. In total, eight studies were included, investigating 16 different polyphenol biomarkers in association with CVD and mortality. Blood and urine were used as biospecimens, and enterolactone, a lignan metabolite, was most often investigated. Three meta-analyses were conducted investigating the association between enterolactone, and all-cause and CVD mortality, and non-fatal myocardial infarction. A 30% and 45% reduced all-cause and CVD mortality risk were revealed at higher enterolactone concentrations. Furthermore, inverse associations were observed between polyphenol biomarkers and all-cause mortality, kaempferol, and acute coronary syndrome. There is evidence to suggest that enterolactone is associated with a lower CVD mortality risk. This emphasises the importance of the role of the microbiota in disease prevention. To strengthen the evidence, more studies are warranted.

[1]  U. Nöthlings,et al.  Association of isoflavone biomarkers with risk of chronic disease and mortality: a systematic review and meta-analysis of observational studies , 2017, Nutrition reviews.

[2]  Guido Schwarzer,et al.  General Package for Meta-Analysis , 2015 .

[3]  J. Dwyer,et al.  Dietary flavonoid intakes and CVD incidence in the Framingham Offspring Cohort , 2015, British Journal of Nutrition.

[4]  R. Gambino,et al.  Dietary flavonoid intake and cardiovascular risk: a population-based cohort study , 2015, Journal of Translational Medicine.

[5]  Josette F. Jones,et al.  Urinary phytoestrogens and cancer, cardiovascular, and all-cause mortality in the continuous National Health and Nutrition Examination Survey , 2015, European Journal of Nutrition.

[6]  S. Bandinelli,et al.  Resveratrol levels and all-cause mortality in older community-dwelling adults. , 2014, JAMA internal medicine.

[7]  E. Rimm,et al.  Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[8]  E. Rimm,et al.  Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial , 2014, BMC Medicine.

[9]  S. Bandinelli,et al.  High concentrations of a urinary biomarker of polyphenol intake are associated with decreased mortality in older adults. , 2013, The Journal of nutrition.

[10]  Xia Wang,et al.  Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies , 2013, British Journal of Nutrition.

[11]  C. Dethlefsen,et al.  Urinary flavonoid excretion and risk of acute coronary syndrome in a nested case-control study. , 2013, The American journal of clinical nutrition.

[12]  J. M. Landete,et al.  Updated Knowledge about Polyphenols: Functions, Bioavailability, Metabolism, and Health , 2012, Critical reviews in food science and nutrition.

[13]  S. Bandinelli,et al.  Comparison of 24-h volume and creatinine-corrected total urinary polyphenol as a biomarker of total dietary polyphenols in the Invecchiare InCHIANTI study. , 2011, Analytica chimica acta.

[14]  David S. Wishart,et al.  Phenol-Explorer: an online comprehensive database on polyphenol contents in foods , 2010, Database J. Biol. Databases Curation.

[15]  M. Clifford,et al.  Dietary phenolics: chemistry, bioavailability and effects on health. , 2009, Natural product reports.

[16]  J. Boer,et al.  Plasma enterolignans are not associated with nonfatal myocardial infarction risk. , 2009, Atherosclerosis.

[17]  S. Rohrmann,et al.  Biomarkers of dietary intake of flavonoids and phenolic acids for studying diet–cancer relationship in humans , 2008, European journal of nutrition.

[18]  A. Minihane,et al.  Biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research , 2007, British Journal of Nutrition.

[19]  L. Arab,et al.  Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. , 2007, The Journal of nutrition.

[20]  E. Feskens,et al.  Intakes of 4 dietary lignans and cause-specific and all-cause mortality in the Zutphen Elderly Study. , 2006, The American journal of clinical nutrition.

[21]  J. Virtamo,et al.  Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers. , 2006, American journal of epidemiology.

[22]  E. Rimm,et al.  Prospective Study on Usual Dietary Phytoestrogen Intake and Cardiovascular Disease Risk in Western Women , 2005, Circulation.

[23]  Liliana Jiménez,et al.  Polyphenols: food sources and bioavailability. , 2004, The American journal of clinical nutrition.

[24]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[25]  J. Salonen,et al.  Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. , 2003, Archives of internal medicine.

[26]  J. Freudenheim,et al.  Biomarkers of nutritional exposure and nutritional status: an overview. , 2003, The Journal of nutrition.

[27]  J. Virtamo,et al.  Use of oral antimicrobials decreases serum enterolactone concentration. , 2002, American journal of epidemiology.

[28]  T. Lakka,et al.  Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study , 1999, The Lancet.

[29]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[30]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[31]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[32]  D. Haytowitz,et al.  USDA develops a database for flavonoids to assess dietary intakes , 2013 .

[33]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[34]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[35]  Gary Williamson,et al.  Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.

[36]  S. P. Akpabio World Health Organisation , 1983, British Dental Journal.